Related by context. All words. (Click for frequent words.) 69 NKTR 68 CRx 67 Hsp# inhibitor 67 Debio 65 AEZS 65 VQD 65 AP# [003] 65 PXD# 65 MGCD# [001] 64 INGN 64 HCV protease inhibitor 64 OXi# 64 PS# [001] 64 CCX# 64 MEK inhibitor 64 MGCD# [002] 64 ARRY 63 ganetespib 63 HGS ETR1 63 MEK inhibitors 63 HspE7 63 obatoclax 62 ALN VSP 62 JAK1 62 AEG# 62 PLK1 SNALP 62 ADXS# 62 ITMN 62 PRTX 61 MORAb 61 4SC 61 RGB # 61 PEG SN# 61 histone deacetylase HDAC inhibitor 61 initiate Phase 1b 61 alvespimycin 61 ENMD # 61 ENMD 61 ISIS # 61 Phase Ib 61 MT# MEDI 61 preclinical studies 61 Hedgehog pathway inhibitor 60 tanespimycin 60 GRN#L 60 OncoVEX GM CSF 60 pan HDAC inhibitor 60 enzastaurin 60 phase IIa clinical 60 JAK inhibitor 60 XL# [003] 60 INCB# [001] 60 IAP inhibitors 60 Perifosine 60 IMGN# 60 XL# XL# XL# 60 AEGR 60 axitinib 59 voreloxin 59 Hsp# inhibitors 59 BiTE antibody 59 RNAi therapeutic 59 PEG Interferon lambda 59 preclinical 59 TOCOSOL Paclitaxel 59 HuLuc# 59 phase IIb clinical 59 vascular disrupting agent 59 PF # [001] 59 Bezielle 59 proteasome inhibitor 59 CCR5 antagonist 59 CORT # 59 XmAb# 59 perifosine 59 MDV# 59 R#/MEM # 59 lintuzumab 59 Phase 2a 59 PEG PAL 59 epothilone 59 tezampanel 59 Atiprimod 59 ALN TTR 59 orally administered inhibitor 59 Panzem R NCD 59 NEUGENE 59 talactoferrin 59 ATL# [001] 59 bafetinib 59 RDEA# 59 Phenoptin 59 oral prodrug 59 Azedra 59 Phase Ib study 58 CR# vcMMAE 58 INCB# [002] 58 Tarvacin TM 58 IMC #B 58 APOPTONE 58 Guanilib 58 CYT# 58 AQ4N 58 BMN 58 PLX# 58 small molecule inhibitor 58 TKM ApoB 58 PRX # 58 CRLX# 58 Sym# 58 elotuzumab 58 favorable pharmacokinetic profile 58 BAY #-# 58 Symadex 58 ALTU 58 HCD# [002] 58 IAP inhibitor 58 pralatrexate 58 hematological malignancies 58 orally bioavailable 58 anticancer agents 58 sapacitabine 58 otelixizumab 58 Aurora kinase 58 XL# XL# 58 CXA 58 PI3K/Akt pathway inhibitor 58 mertansine 58 HCV protease 58 forodesine 58 Phase 2a clinical 58 pertuzumab 58 ongoing Phase 1b 58 Phase 1b 58 Allovectin 7 R 58 MAGE A3 ASCI 58 selective androgen receptor modulator 58 INNO 58 ARQ 58 PDX pralatrexate 58 CoFactor 58 Tyrima 58 ELND# 58 seliciclib 57 CEQ# 57 Phase #b/#a clinical 57 PSMA ADC 57 dacetuzumab 57 OncoVEX 57 Tarvacin 57 HGS# 57 HCV protease inhibitors 57 XL# XL# XL# XL# 57 HZT 57 NGX# 57 XOMA 57 Exelixis compounds 57 iCo 57 elesclomol 57 cannabinor 57 REOLYSIN ® 57 Archexin 57 cyclophilin inhibitor 57 preclinical efficacy 57 Traficet EN 57 polymerase inhibitor 57 JVRS 57 huC# DM4 57 DXL# 57 Serdaxin 57 GALNS 57 investigational humanized monoclonal antibody 57 anticancer compound 57 antagomirs 57 Clay B. Siegall 57 telaprevir VX 57 Phase Ib clinical trials 57 HGS ETR2 57 bavituximab 57 drug conjugate 57 humanized monoclonal antibody 57 Azixa 57 liposomal formulation 57 HDAC inhibitor 57 cancer immunotherapies 57 IMC A# 57 radiation sensitizer 57 Exelixis XL# 57 TREANDA 57 MOZOBIL 57 metaglidasen 57 Anticalin 57 PCK# 57 mapatumumab 57 ANG# 57 Aurora kinase inhibitor 57 GAP #B# 57 phase Ib 57 Phase 2b trial 57 HCV nucleotide polymerase inhibitor 57 DOS# 57 SARMs 57 relapsed refractory multiple myeloma 57 VitiGam 57 preclinically 57 Phase 1b trial 56 LymphoStat B 56 CCR9 antagonist 56 celgosivir 56 EndoTAG TM -1 56 ImmunoVEX HSV2 56 entinostat 56 AAG geldanamycin analog 56 vascular disrupting agents 56 hematological cancers 56 COU AA 56 novel topoisomerase 56 Panzem R 56 CD# antibody [001] 56 protein kinase inhibitor 56 tesetaxel 56 Phase 2a trial 56 PSN# [002] 56 LEVADEX 56 ARRY # 56 GSK # 56 JAK inhibitors 56 Carfilzomib 56 AZD# 56 CCR2 56 CA4P 56 ASONEP 56 Phase Ib II 56 iSONEP 56 deforolimus 56 Alpharadin 56 systemic RNAi therapeutic 56 HIV integrase inhibitors 56 neratinib 56 ELACYT 56 Omacetaxine 56 Actilon 56 Belinostat 56 Gemin X 56 ostarine 56 novel anticancer 56 lesinurad 56 JAK2 inhibitor 56 AzaSite Plus 56 Bicifadine 56 PrevOnco ™ 56 CBLC# 56 Hsp# inhibition 56 MAP# 56 rNAPc2 56 selective androgen receptor modulators 56 IDX# 56 Panzem 56 selective kinase inhibitor 56 Nanobody 56 MAXY alpha 56 eniluracil 56 oritavancin 56 YONDELIS 56 non nucleoside inhibitor 56 Epothilone D 56 vosaroxin 56 Aplidin 56 TACI Ig 56 tivozanib 56 Sphingomab 56 Abiraterone acetate 56 SERMs 56 Azedra TM 56 AACR NCI EORTC 56 OHR/AVR# 56 TG# [003] 56 Phase #/#a trial 56 solid tumors 56 Phase Ib clinical 56 retaspimycin 56 Hedgehog pathway 56 T DM1 56 humanized anti 56 investigational compounds 56 compound AEZS 56 compound ITMN 56 R roscovitine 55 CYC# 55 HER2 positive metastatic breast 55 Aurexis 55 Talactoferrin 55 AEOL # 55 Allovectin 7 ® 55 HuMax EGFr 55 Sapacitabine 55 Curaxin CBLC# 55 Alocrest 55 alpha folate receptor 55 GSK# [001] 55 bendamustine 55 EGEN 55 HQK 55 Phase IIa clinical 55 non nucleoside HCV 55 BiTE 55 AKT inhibitor 55 Varespladib 55 Neuradiab 55 investigational compound 55 AVN# [001] 55 RG# ITMN 55 ponatinib 55 pradefovir 55 Asentar 55 ApoB SNALP 55 Hedgehog antagonist 55 vilazodone 55 TG MV 55 RVX 55 preclinical compounds 55 histone deacetylase HDAC 55 immunomodulator 55 PNP inhibitor 55 HCV polymerase inhibitors 55 Amigal 55 epothilones 55 virus HCV protease inhibitor 55 belinostat 55 Ceflatonin 55 metastatic hormone refractory 55 Synavive 55 novel mTOR inhibitor 55 CYT# potent vascular disrupting 55 targeting CD# 55 Virulizin ® 55 Targretin 55 histone deacetylase inhibitor 55 polymerase inhibitors 55 isoform selective 55 tubulin inhibitor 55 Phase IIa trial 55 TBC# 55 OvaRex R 55 HDAC Inhibitor 55 oxidative stress inducer 55 Phase 2b clinical 55 investigational pan BCR 55 Alzhemed TM 55 bevirimat 55 HuMax CD4 55 Triolex 55 Solazed TM 55 Cloretazine R VNP#M 55 nicotinic alpha 7 55 valopicitabine 55 PDE4 inhibitor 55 BIBW 55 Corlux 55 pomalidomide 55 amrubicin 55 mitogen activated ERK kinase 55 picoplatin 55 huN# DM1 55 siRNA therapeutic 55 seliciclib CYC# 55 carfilzomib 55 CERE 55 NS4A 55 bortezomib Velcade 55 LY# [003] 55 Cotara 55 oncolytic 55 anidulafungin 55 ALN PCS 55 EOquin 55 IRX 2 55 tyrosine kinase inhibitor 55 nanoviricides 55 LY# [002] 55 tesmilifene 55 oral picoplatin 55 Phase IIb trial 55 SCH # 55 tamibarotene 54 aflibercept 54 imetelstat 54 adecatumumab 54 Poly ICR 54 kinase inhibitors 54 anticancer agent 54 veltuzumab 54 REOLYSIN R 54 Phase 1b clinical 54 Stedivaze 54 ONCONASE 54 PARP inhibitor 54 CTCE 54 Exherin TM 54 DAVANAT 54 Trofex 54 tremelimumab 54 Bendavia 54 BNC# 54 UVIDEM 54 darapladib 54 JAK2 inhibitors 54 Preclinical 54 IIa trial 54 LBH# 54 Phase 2b study 54 Phase III clinical 54 Annamycin 54 Preclinical studies 54 selective inhibitor 54 forodesine HCl 54 dacetuzumab SGN 54 antisense drug 54 bortezomib 54 NNR Therapeutics 54 Phase #b/#a 54 custirsen 54 trastuzumab DM1 T DM1 54 Onconase 54 RhuDex ® 54 CD# CEA 54 Kevetrin 54 ALN RSV# 54 Tesetaxel 54 proteasome inhibitors 54 antiviral activity 54 anti angiogenic 54 Multimeric 54 anticoagulant reversing agent 54 generation antisense 54 phase IIa 54 docetaxel Taxotere R 54 LEP ETU 54 ARIKACE ™ 54 Aplidin R 54 HuMax CD# 54 Restanza 54 immunomodulating 54 ThermoDox R 54 MAbs 54 small molecule defensin 54 evaluating satraplatin 54 BCIRG 54 receptor tyrosine kinase inhibitor 54 ZYBRESTAT 54 prasugrel CS 54 IPL# 54 oral antiviral 54 Phase IIa trials 54 multi kinase inhibitor 54 incyclinide 54 Talabostat 54 Zenvia ™ 54 elvucitabine 54 Protexia R 54 lorvotuzumab mertansine 54 Phase IIb 54 LibiGel Phase III 54 LE SN# 54 Anticalin R 54 torezolid phosphate 54 TLR7 54 castrate resistant prostate cancer 54 xenograft models 54 renin inhibitors 54 randomized discontinuation trial 54 Amrubicin 54 talabostat 54 Insegia 54 DermaVir Patch 54 Ozarelix 54 Aflibercept 54 Phase IIb clinical 54 NEUMUNE 54 DAVANAT R 54 HCV polymerase inhibitor 54 Zalbin 54 DR Cysteamine 54 Nexavar ® 54 FGFR 54 Zolinza 54 hematologic malignancies 54 targeted radiotherapeutic 54 PI3K inhibitor 54 MOR# 54 #ME# 54 CBLB# 54 palifosfamide Zymafos TM 54 HCV NS5B polymerase 54 ALN TTR# 54 castration resistant prostate cancer 54 ADVEXIN 54 Viprinex 54 kinase inhibitor 54 Aurora kinase inhibitors 54 SRT# [003] 54 NEUGENE antisense 54 ridaforolimus 54 resistant ovarian cancer 54 MB# [004] 54 Mipomersen 54 cilengitide 54 farletuzumab 54 Zybrestat 54 Xanafide 54 ONX 54 Pimavanserin 54 angiogenesis inhibitors 54 antitumor activity 54 multitargeted 54 Phase 2b 54 OMP #M# 54 lintuzumab SGN 54 IMA# 54 novel VDA molecule 54 EGFR HER2 54 phase IIb 54 PrevOnco 54 systemically administered 53 ASA# 53 Lenocta 53 Apoptone 53 palifosfamide 53 CORLUX CORT # 53 pivotal Phase III 53 delta isoform 53 MLN# 53 Chemophase 53 thymalfasin 53 oral proteasome inhibitor 53 oral JAK1 53 Indibulin 53 NXL# 53 Cloretazine ® 53 potent inhibitor 53 SNALP technology 53 zanolimumab 53 PRT# 53 HDAC inhibitors 53 novel histone deacetylase 53 Thiovir 53 THR beta agonist 53 investigational monoclonal antibody 53 Epothilones 53 INC# 53 Allovectin 7 53 oral ridaforolimus 53 EZN 53 elacytarabine 53 adecatumumab MT# 53 Curaxin 53 ALKS 53 ispinesib 53 TELINTRA 53 KSP inhibitor 53 Bortezomib 53 Intravenous CP 53 5 HT6 antagonist 53 Reolysin 53 NVA# 53 Cethromycin 53 GVAX ® 53 bicifadine 53 siRNA therapeutics 53 Prednisporin 53 ProLindac 53 nanopharmaceutical 53 immunomodulatory 53 ThermoDox ® 53 EndoTAGTM 1 53 fosbretabulin 53 Daclizumab 53 HGS ETR1 mapatumumab 53 brostallicin 53 Imprime PGG 53 A3 adenosine receptor 53 DAVANAT ® 53 GLP toxicology studies 53 BZL# 53 TRAIL receptor antibodies 53 initiated Phase 1b 53 NP2 Enkephalin 53 small molecule 53 velafermin belinostat 53 Nanobodies 53 metastatic melanoma 53 MPS IVA 53 CCR5 mAb 53 Proxinium TM 53 Kahalalide F 53 BEMA TM Fentanyl 53 oral Hsp# inhibitor 53 sodium glucose cotransporter 53 TKB# 53 ospemifene 53 Vicinium TM 53 therapeutic monoclonal antibody 53 small molecule tyrosine 53 molecularly targeted 53 evaluating tivozanib 53 Cannabinor 53 ThermoDox 53 Novelos 53 L BLP# 53 KRN# 53 VEGF Trap 53 PI3K inhibitors 53 tafamidis 53 daclizumab 53 HSP# inhibitor 53 NovaBay 53 HIV integrase inhibitor 53 VentiRx 53 FOLOTYN ® 53 BRAF inhibitor 53 Myrexis 53 Tarmogen 53 OPAXIO 53 phase 2a 53 Cloretazine R 53 perifosine KRX 53 UPLYSO 53 oncology indications 53 TRO# 53 TLR9 agonists 53 EpCAM 53 Azedra ™ 53 CD# monoclonal antibody 53 leading oral taxane 53 davunetide intranasal AL 53 anti CD# antibodies 53 Shigamabs ® 53 non nucleoside polymerase 53 integrase inhibitor 53 anti leukemic 53 cMET 53 MAXY G# 53 tasimelteon 53 ChemoCentryx 53 radezolid 53 HE# [002] 53 MEK Inhibitor 53 Viramidine 53 CGEN # 53 MET amplification 53 milatuzumab 53 Neo Kidney Augment ™ 53 tyrosine kinase inhibitors 53 GRN# 53 oral FTY# 53 Aclidinium 53 PARP inhibitors 53 maturation inhibitor 53 PORxin TM 53 Amplimexon 53 Marqibo 53 REOLYSIN 53 EGFR inhibitors 53 OMNARIS HFA 53 nonclinical studies 53 nanoviricide drug 53 Proellex TM 53 Opexa 53 Litx 53 drug GAP #B# 53 generation proteasome inhibitor 53 taxane resistant 53 relapsed multiple myeloma 53 compound INCB# 53 confirmatory Phase 3 53 Æterna Zentaris 53 anticancer therapies 53 #D#C# 53 BCX# 53 ANX 53 oncolytic virus 53 signal transduction inhibitor 52 volociximab 52 Romidepsin 52 ANYARA 52 investigational drug 52 telomerase inhibitor drug 52 TRIOLEX 52 antiangiogenic activity 52 adipiplon 52 dasatinib Sprycel 52 reslizumab 52 XYOTAX TM 52 oral isoform selective HDAC 52 APD# 52 ATHX 52 refractory PTCL 52 delafloxacin 52 phase IIb study 52 dose escalation trial 52 dose escalation Phase 52 mipomersen 52 Hedgehog Pathway Inhibitor 52 tiapamil 52 MEK inhibitor RDEA# 52 candidate CRLX# 52 small molecule inhibitors 52 trastuzumab Herceptin R 52 Oral NKTR 52 ASG 5ME 52 ozarelix 52 vemurafenib 52 OMAPRO 52 Eniluracil 52 OncoVex 52 GMX# 52 Seliciclib 52 FluCide 52 resolvin 52 Squalamine 52 refractory CLL 52 ATL# [002] 52 cell malignancies 52 S/GSK# 52 tipifarnib 52 ProMune 52 drug pipeline TAFA# 52 Akt inhibitor 52 XMT 52 IKK epsilon 52 registrational trial 52 Voreloxin 52 CK # 52 Dapagliflozin 52 CRF1 receptor antagonist 52 Menerba 52 MGd 52 blinatumomab 52 indibulin 52 Sudhir Agrawal D.Phil 52 ZFP Therapeutics 52 P#X# antagonist 52 ON #.Na 52 DsiRNA 52 Locteron 52 trabectedin 52 vaccines oncolytic virus 52 omacetaxine 52 Phase 1b clinical trials 52 REP# 52 metastatic castration resistant 52 Icatibant 52 Aganocide R 52 T#I [002] 52 Virulizin R 52 ZFP Therapeutic 52 brivaracetam 52 antisense drugs 52 prodrug 52 visilizumab 52 dose escalation 52 glioblastoma multiforme GBM 52 teduglutide 52 Lu AA# 52 elagolix 52 Fibrillex TM 52 Tamibarotene 52 NS#/#A protease 52 PTH analogue 52 INT# [002] 52 PI3 kinase inhibitors 52 TRV# [001] 52 Phase III pivotal 52 BHT DNA 52 XL# anticancer compounds 52 Factor VIIa 52 MTP inhibitor 52 imatinib Gleevec ® 52 thiazolides 52 ThermoDox ® clinical 52 MultiStem 52 XL# inhibits 52 squalamine 52 PKC# 52 Vilazodone 52 Palifosfamide 52 Dr. Aiping Young 52 ocrelizumab 52 erlotinib Tarceva ® 52 oral bioavailability 52 Tarvacin Anti Viral 52 antisense 52 R#/MEM 52 induce apoptosis 52 LibiGel ® 52 TKM PLK1 52 registrational 52 novel immunomodulatory 52 trastuzumab DM1 52 Phase 2a Clinical Trial 52 IMiDs 52 IgG1 antibody 52 Corcept 52 IgG1 monoclonal antibody 52 Solorel TM 52 Lorianne Masuoka MD 52 ProSavin 52 LentiVector technology 52 Revimmune 52 class mGluR5 inhibitor 52 ibudilast 52 anti amnesic 52 Hsp# Inhibitor 52 pharmacological chaperone 52 retapamulin 52 generation Hsp# inhibitor 52 multicenter Phase II 52 CCX# B 52 Relivar 52 FavId 52 RAV# 52 vinca alkaloid 52 T#I mutant 52 RNAi therapeutic targeting 52 demonstrated antitumor activity 52 dose escalation study 52 Alnylam #x# 52 sorafenib tablets 52 advanced carcinoid 52 ANA# 52 Anticalins 52 Lovaxin C 52 SUCCEED trial 52 Phase IIb clinical trials 52 PHX# 52 Blinatumomab 52 ALD# 52 DB# [003] 52 Phase IIa 52 refractory Hodgkin lymphoma 52 Elagolix 52 refractory multiple myeloma 52 Deforolimus 52 targeted kinase inhibitor 52 Tovaxin 52 Phase II 52 CDK cyclin dependent 52 OMP #R# 52 cetuximab Erbitux ® 52 lexidronam injection 52 rFIXFc 52 generation HCV protease 52 mTOR inhibitors 52 Lenocta TM 52 highly selective adenosine 52 therapeutic antibody 52 epigenetic therapies 52 AAG KOS 52 ulimorelin 52 PEGylated 52 GW# [003] 52 investigational hepatitis C 52 interferon lambda 52 retaspimycin hydrochloride 51 synthetic retinoid 51 bortezomib Velcade ® 51 Atu# 51 CINTREDEKIN BESUDOTOX 51 methionine aminopeptidase 51 telomerase inhibitor 51 TLR antagonists 51 poly ADP ribose polymerase 51 microtubule targeting 51 EORTC NCI AACR Symposium 51 TLR agonists 51 methylnaltrexone 51 HERmark 51 ICAAC 51 Valortim 51 triphendiol 51 XmAb 51 SAR# [004] 51 ARC# [001] 51 Celator 51 optimized siRNA 51 TriRima 51 Anavex #-# 51 anti CD# antibody 51 BiTE antibodies 51 oncology therapeutics 51 Cytokinetics Incorporated NASDAQ CYTK 51 Solazed 51 mAb 51 INCB# [003] 51 FTY# 51 ocular formulation 51 selective modulator 51 HuCAL antibodies 51 FLT3 51 ToGA 51 favorable tolerability 51 AeroLEF 51 MT#/MEDI-# 51 Excellarate 51 preclinical pharmacokinetic 51 glucagon receptor 51 dalbavancin 51 BrachySil TM 51 nucleoside 51 Onco TCS 51 TELCYTA 51 NU# [001] 51 Virulizin 51 Genz # 51 oral kinase inhibitor 51 RhuDex R 51 depsipeptide 51 ularitide 51 Fodosine 51 immunotherapeutic agent 51 BRIM2 51 Phase Ia 51 ixabepilone 51 human monoclonal antibody 51 personalized immunotherapy 51 MNTX 51 ESBA# 51 oral Azacitidine 51 potent anticancer 51 ketolide antibiotic 51 HepeX B TM 51 Nanobody ® 51 Androxal TM 51 BCR ABL inhibitors 51 pan Bcl 2 51 PEGPH# 51 NCCTG 51 Phase III 51 potent antitumor activity 51 Ophena TM 51 eltrombopag 51 ADI PEG 51 JAK3 51 tezampanel NGX# 51 alemtuzumab Campath 51 TAFA# 51 teplizumab 51 vismodegib 51 vivo efficacy 51 sodium Injection 51 chemically modified siRNA 51 Tarceva TM 51 NS5b 51 angiogenesis inhibitor 51 FOLFOX6 chemotherapy regimen 51 Phase #b/#a trial 51 lomitapide 51 NTDDS 51 taxane 51 Ceflatonin R 51 Phase IIb trials 51 brentuximab vedotin SGN 51 EOquin TM 51 InNexus 51 TRC# 51 Nasulin 51 CD4 monoclonal antibody 51 M2 subunit 51 IMPDH inhibitor 51 humanized monoclonal antibodies 51 renin inhibitor 51 ongoing Phase IIIb 51 BAL# [002] 51 IL# PE#QQR 51 IND enabling 51 Aganocide ® 51 KNS # 51 selective inhibition 51 refractory APL 51 midstage trials 51 exon skipping 51 BGC# 51 ATL/TV# 51 ErbB3 51 acyclovir Lauriad R 51 Pralatrexate 51 EndoTAG TM 51 cethromycin 51 CB2 selective receptor agonist 51 Reverset 51 immunotherapeutic 51 TPI ASM8 51 Personalized Immunotherapy 51 Zalicus 51 ORMD 51 Gemzar ® 51 Dr. Marlies Sproll 51 ANAVEX #-# [003] 51 Homspera